Evusheld, manufactured by AstraZeneca, is indicated for pre-exposure and treatment in mild and moderate cases of the disease; agency points to a significant drop in effectiveness
A National Health Surveillance Agency (Anvisa) temporarily suspended the authorization for the emergency use of the drug Evusheld (Tixagevimab + Cilgavimab), manufactured by AstraZenecafor the treatment of Covid-19. The decision issued this Tuesday, 7, is due to the “significant drop in activity against the variants of concern of the new coronavirus circulating in the country”. The agency indicates that, if there are lots of the drug in Brazilian territory, the company must inform health professionals “about the ineffectiveness of the drugs against the circulating variants of Sars-Cov-2”. The suspension takes place by unanimous decision of the collegiate board and will be maintained until data are presented that prove its effectiveness of the drug against the Sars-CoV-2 variants circulating in the country. Evusheld is indicated for pre-exposure and treatment of Covid-19 in mild to moderate cases, for patients who are at high risk of progression and worsening of the disease.
